o-Methylsterigmatocystin (OMST) is a mycotoxin produced by the fungus Aspergillus. It is a structurally related to sterigmatocystin, a known carcinogenic compound. OMST has been found to be mutagenic in bacterial and mammalian cell systems. It has also been shown to be toxic to animals, with studies demonstrating liver damage and immunosuppression. The importance of studying OMST stems from its potential for contamination of food and feed, as well as its possible role in human health issues. Research on OMST focuses on understanding its biosynthesis, toxicity, and mechanisms of action. Studies are also aimed at developing methods for detection and control of this mycotoxin in food and environmental samples.'
ID Source | ID |
---|---|
PubMed CID | 104940 |
CHEBI ID | 18171 |
SCHEMBL ID | 1055409 |
MeSH ID | M0119135 |
Synonym |
---|
CHEBI:18171 |
(3ar,12cs)-6,8-dimethoxy-3a,12c-dihydro-7h-furo[3',2':4,5]furo[2,3-c]xanthen-7-one |
o-methyl sterigmatocystin |
7-o-methylsterigmatocystin |
sterigmatocystin, o-methyl- |
7h-furo(3',2':4,5)furo(2,3-c)xanthen-7-one, 3a,12c-dihydro-6,8-dimethoxy-, (3ar-cis)- |
7h-furo(3',2':4,5)furo(2,3-c)xanthen-7-one, 3a,12c-dihydro-6,8-dimethoxy-, (3ar,12cs)- |
C03686 |
o-methylsterigmatocystin |
17878-69-2 |
8-o-methylsterigmatocystin |
LMPK10000003 |
unii-kzc4vx8l3n |
kzc4vx8l3n , |
SCHEMBL1055409 |
J-011402 |
methylsterigmatocystin, o- |
6,8-dimethoxy-3a,12c-dihydro-7h-furo[3',2':4,5]furo[2,3-c]xanthen-7-one |
DTXSID30939117 |
Q27102869 |
11,15-dimethoxy-6,8,20-trioxapentacyclo[10.8.0.02,9.03,7.014,19]icosa-1,4,9,11,14(19),15,17-heptaen-13-one |
(3s,7r)-11,15-dimethoxy-6,8,20-trioxapentacyclo[10.8.0.02,9.03,7.014,19]icosa-1,4,9,11,14(19),15,17-heptaen-13-one |
7h-furo[3',2':4,5]furo[2,3-c]xanthen-7-one, 3a,12c-dihydro-6,8-dimethoxy-, (3ar,12cs)- |
(3ar,12cs)-3a,12c-dihydro-6,8-dimethoxy-7h-furo[3',2':4,5]furo[2,3-c]xanthen-7-one |
Class | Description |
---|---|
sterigmatocystins | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Pathway | Proteins | Compounds |
---|---|---|
aflatoxins B1 and G1 biosynthesis | 2 | 18 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (19.05) | 18.7374 |
1990's | 7 (33.33) | 18.2507 |
2000's | 8 (38.10) | 29.6817 |
2010's | 2 (9.52) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.34) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (4.55%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 21 (95.45%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |